SCHEMBL2170517

SCHEMBL2170517

CCc1nc2c(OC)ccc(-c3ccc4[nH]c(=O)ccc4c3)c2o1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.39
OGT O15294 3/20 0.39
MAPT P10636 2/20 0.39
TP53 P04637 1/20 0.39
CA12 O43570 1/20 0.36
CA9 Q16790 1/20 0.36
PDE3A Q14432 3/20 0.35
PDE4B Q07343 2/20 0.35
PDE3B Q13370 1/20 0.34
ADORA3 P0DMS8 1/20 0.34
TLR8 Q9NR97 2/20 0.34
TLR7 Q9NYK1 2/20 0.34
TERT O14746 1/20 0.34
CYP1A1 P04798 1/20 0.33
CYP1B1 Q16678 1/20 0.33
F11 P03951 1/20 0.33
TNKS2 Q9H2K2 1/20 0.33
AR P10275 1/20 0.33
MEN1 O00255 1/20 0.33
NPC1 O15118 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2170590 0.80 PDE4B (0.52) LMNAOGTMAPTTP53CA12
SCHEMBL2172749 0.78 LMNA (0.44) LMNAOGTMAPTTP53CA12
SCHEMBL2171497 0.75 LMNA (0.42) LMNAOGTMAPTTP53CA12
SCHEMBL3120931 0.75 PDE4B (0.45) LMNAMAPTTP53PDE3APDE4B
SCHEMBL2172286 0.74 TNKS2 (0.43) LMNAOGTMAPTTP53CA12
SCHEMBL2172288 0.74 GLO1 (0.43) LMNAOGTMAPTTP53CA12
SCHEMBL2173289 0.74 PDE4B (0.46) LMNAOGTMAPTTP53CA12
SCHEMBL2170674 0.73 LMNA (0.40) LMNAOGTMAPTTP53CA12
SCHEMBL2172765 0.73 PDE4B (0.53) LMNAOGTMAPTTP53PDE3A
SCHEMBL2184439 0.73 PDE4B (0.52) LMNAOGTMAPTTP53CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2348018-A1 HETEROCYCLIC BIARYL DERIVATIVE, AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT Kyorin Pharmaceutical Co., Ltd. (JP) 2011-07-27 EP disclosed
US-20110178041-A1 HETEROCYCLIC BIARYL DERIVATIVE AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT KYORIN PHARMACEUTICAL CO., LTD. (JP) 2011-07-21 US disclosed
US-20110178041-A1 HETEROCYCLIC BIARYL DERIVATIVE AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT KYORIN PHARMACEUTICAL CO., LTD. (JP) 2011-07-21 US disclosed
US-20110178041-A1 HETEROCYCLIC BIARYL DERIVATIVE AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT KYORIN PHARMACEUTICAL CO., LTD. (JP) 2011-07-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178041-A1 HETEROCYCLIC BIARYL DERIVATIVE AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT PDE3A, PDE2A, PDE3B LMNA 2863/4885OGT 3902/4885MAPT 4548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.